Tofacitinib citrate for the treatment of nail dystrophy associated with alopecia universalis

JAMA Dermatology

Volumn 152, Issue 4, 2016, Pages 492-493

  Dhayalan, Arjun ^a   King, Brett A ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; TOFACITINIB; JANUS KINASE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ALOPECIA; ALOPECIA UNIVERSALIS; ARTICLE; CASE REPORT; CYTOPENIA; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; HAIR GROWTH; HUMAN; HYPERTRANSAMINASEMIA; INFECTION; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MALE; MORNING DOSAGE; NAIL DYSTROPHY; ONYCHOLYSIS; PAIN; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; ANTAGONISTS AND INHIBITORS; COMPLICATION; NAIL; NAIL DISEASES; PATHOLOGY;

ADULT; ALOPECIA; FEMALE; HUMANS; JANUS KINASES; MALE; NAIL DISEASES; NAILS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES;

EID: 84963716868     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2015.3772     Document Type: Article

References (5)

1. Gordon KA, Vega JM, Tosti A. Trachyonychia: a comprehensive review. Indian J Dermatol Venereol Leprol. 2011;77(6):640-645.
2. Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014;134(12):2988-2990.
3. Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9): 1043-1049.
4. Jabbari A, Dai Z, Xing L, et al. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine. 2015;2(4): 351-355.
5. Kasumagic-Halilovic E, Prohic A. Nail changes in alopecia areata: frequency and clinical presentation. J Eur Acad Dermatol Venereol. 2009;23(2): 240-241.